![](https://endpts.com/wp-content/uploads/2023/01/David-Loew-Ipsen-tile.jpg)
David Loew, Ipsen CEO
Ipsen pays Day One $111M upfront for ex-US rights to pediatric brain tumor drug
In another move to boost its oncology portfolio, Ipsen is handing Day One Biopharmaceuticals $111 million upfront so it can take the pediatric brain tumor …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.